Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

[단독] 반구대병원, 한달 안 ‘전원 완료’에 복지부 ‘동의’…“무책임” 비판

Original Korean Read in English

Ulsan's Banmu Hospital recently announced its plan to complete total readmissions within a month, and the Ministry of Health and Welfare has endorsed this decision. This comes after a death case, and concerns have been raised about the hasty readmissions leading to irresponsible behavior. According to the Ministry of Health and Welfare, Banmu Hospital is planning to submit individual readmission plans by August 19 and complete the total readmission by September 3.

The Ministry has expressed its agreement with this plan, stating that they will support Banmu Hospital in providing necessary arrangements for discharged patients, including disabled individuals who wish to live independently in the community. However, a coalition of 30 local organizations has submitted an urgent request to the National Human Rights Commission, urging them to establish a joint emergency committee for the preparation of a comprehensive response to the readmission situation.

Critics argue that the hasty readmissions could result in further institutionalization and human rights violations. The former director of the National Gwangju Hospital, Jin Guk, has criticized the Ministry for leaving the responsibility to individual hospitals, stating that it is not a simple matter of sending patients to other facilities.

He emphasized the need for a unified approach involving the Ministry, local governments, and various organizations to address the issue comprehensively.

Written by urgent.news from Hankyoreh's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at hani.co.kr →

More in Health & Medicine

Celltrion Expands Market Presence in Spain and Portugal Through Tender Wins

Celltrion is rapidly strengthening its presence in Spain and Portugal, securing a series of government and regional tenders while expanding sales and marketing activities to drive prescriptions and…

  • Celltrion wins government tenders in Spain and Portugal, expanding market presence.
  • Omlyclo biosimilar dominates Spanish market with 90% share by June.
  • Actemra and other biosimilars gain significant market share in Spain and Portugal.

More from Wednesday 12 August →